Lindahl is serving as legal advisor when ISR carries out a fully underwritten rights issue of units to shareholders. If the issue is fully subscribed, approximately SEK 71.7 million will be raised for the company on shares issued before costs and expenses relating to the offering. If the issue is fully subscribed and all TO1 warrants are fully exercised within the parameters for the issuance of units, this may raise additional capital of between SEK 23.9 million and SEK 71.7 million for the company, depending on the exercise price. If the issue is fully subscribed and all TO2 warrants are fully exercised within the parameters for the issuance of units, this may raise additional capital of at least SEK 23.9 million for the company, depending on the exercise price. The subscription period for the rights issue runs from 15 May 2020 to 29 May 2020.
ISR Immune System Regulation Holding AB is an innovation-driven research company within the area of immunotherapy. It is listed on the Nasdaq First North Growth Market and is based at the Karolinska Hospital in Stockholm, Sweden. The company is committed to developing immunostimulants, which are drugs that activate the body’s immune system, to treat chronic infections and cancer. The company has two drug development platforms: Immunorhelins, consisting of immune-stimulating Gonadotropin-releasing hormones, where the initial indication is for HIV, and Immunolides, defined as immunostimulating macrolides, where the initial indication is for cancer and HBV, and which are also being evaluated for the treatment of the coronavirus.
The team assigned by the law firm Lindahl to provide ISR with legal support in connection with the rights issue comprised Monica Lagercrantz (responsible partner), Ola Svanberg, Nicklas Bexelius and Lisa Liljekvist. The securities broker Mangold Fondkommission AB served as the financial advisor.